S&P 500   4,580.77 (+0.64%)
DOW   35,633.07 (+0.40%)
QQQ   382.38 (+0.63%)
AAPL   152.03 (+2.14%)
MSFT   322.29 (-0.27%)
FB   311.45 (-0.25%)
GOOGL   2,908.99 (-0.53%)
TSLA   1,061.50 (+2.28%)
AMZN   3,408.56 (+0.47%)
NVDA   246.67 (+0.88%)
BABA   169.85 (+0.37%)
NIO   39.63 (+0.81%)
CGC   12.96 (+1.41%)
GE   104.26 (+0.39%)
AMD   122.16 (-0.10%)
MU   69.82 (+2.32%)
T   25.51 (+1.80%)
F   17.06 (+9.99%)
ACB   6.93 (+1.32%)
DIS   169.77 (+0.13%)
PFE   43.22 (+0.58%)
BA   206.41 (-0.10%)
AMC   36.03 (+3.65%)
S&P 500   4,580.77 (+0.64%)
DOW   35,633.07 (+0.40%)
QQQ   382.38 (+0.63%)
AAPL   152.03 (+2.14%)
MSFT   322.29 (-0.27%)
FB   311.45 (-0.25%)
GOOGL   2,908.99 (-0.53%)
TSLA   1,061.50 (+2.28%)
AMZN   3,408.56 (+0.47%)
NVDA   246.67 (+0.88%)
BABA   169.85 (+0.37%)
NIO   39.63 (+0.81%)
CGC   12.96 (+1.41%)
GE   104.26 (+0.39%)
AMD   122.16 (-0.10%)
MU   69.82 (+2.32%)
T   25.51 (+1.80%)
F   17.06 (+9.99%)
ACB   6.93 (+1.32%)
DIS   169.77 (+0.13%)
PFE   43.22 (+0.58%)
BA   206.41 (-0.10%)
AMC   36.03 (+3.65%)
S&P 500   4,580.77 (+0.64%)
DOW   35,633.07 (+0.40%)
QQQ   382.38 (+0.63%)
AAPL   152.03 (+2.14%)
MSFT   322.29 (-0.27%)
FB   311.45 (-0.25%)
GOOGL   2,908.99 (-0.53%)
TSLA   1,061.50 (+2.28%)
AMZN   3,408.56 (+0.47%)
NVDA   246.67 (+0.88%)
BABA   169.85 (+0.37%)
NIO   39.63 (+0.81%)
CGC   12.96 (+1.41%)
GE   104.26 (+0.39%)
AMD   122.16 (-0.10%)
MU   69.82 (+2.32%)
T   25.51 (+1.80%)
F   17.06 (+9.99%)
ACB   6.93 (+1.32%)
DIS   169.77 (+0.13%)
PFE   43.22 (+0.58%)
BA   206.41 (-0.10%)
AMC   36.03 (+3.65%)
S&P 500   4,580.77 (+0.64%)
DOW   35,633.07 (+0.40%)
QQQ   382.38 (+0.63%)
AAPL   152.03 (+2.14%)
MSFT   322.29 (-0.27%)
FB   311.45 (-0.25%)
GOOGL   2,908.99 (-0.53%)
TSLA   1,061.50 (+2.28%)
AMZN   3,408.56 (+0.47%)
NVDA   246.67 (+0.88%)
BABA   169.85 (+0.37%)
NIO   39.63 (+0.81%)
CGC   12.96 (+1.41%)
GE   104.26 (+0.39%)
AMD   122.16 (-0.10%)
MU   69.82 (+2.32%)
T   25.51 (+1.80%)
F   17.06 (+9.99%)
ACB   6.93 (+1.32%)
DIS   169.77 (+0.13%)
PFE   43.22 (+0.58%)
BA   206.41 (-0.10%)
AMC   36.03 (+3.65%)
NASDAQ:ZY

Zymergen Stock Forecast, Price & News

$10.46
+0.18 (+1.75 %)
(As of 10/28/2021 10:15 AM ET)
Add
Compare
Today's Range
$10.07
$10.46
50-Day Range
$9.79
$14.19
52-Week Range
$7.85
$52.00
Volume
867 shs
Average Volume
909,384 shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive ZY News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymergen and its competitors with MarketBeat's FREE daily newsletter.


About Zymergen

Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe. The company has a platform that treats the genome as a search space, to identify genetic changes that improve the economics for its customers' bio-based products for a range of industries, including chemicals and materials, agriculture, and pharmaceuticals. Zymergen's platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Employees
758
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.07 billion
Next Earnings Date
11/3/2021 (Confirmed)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.12 out of 5 stars

Basic Materials Sector

202nd out of 226 stocks

Commercial Physical Research Industry

21st out of 27 stocks

Analyst Opinion: 1.8Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Zymergen (NASDAQ:ZY) Frequently Asked Questions

Is Zymergen a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zymergen in the last twelve months. There are currently 4 sell ratings and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Zymergen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZY, but not buy additional shares or sell existing shares.
View analyst ratings for Zymergen
or view top-rated stocks.

What stocks does MarketBeat like better than Zymergen?

Wall Street analysts have given Zymergen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zymergen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zymergen's next earnings date?

Zymergen is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Zymergen
.

How can I listen to Zymergen's earnings call?

Zymergen will be holding an earnings conference call on Wednesday, November 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Zymergen's earnings last quarter?

Zymergen Inc. (NASDAQ:ZY) released its quarterly earnings results on Monday, August, 16th. The company reported ($1.30) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.03) by $0.27. The firm had revenue of $5.89 million for the quarter, compared to analysts' expectations of $5.75 million.
View Zymergen's earnings history
.

What guidance has Zymergen issued on next quarter's earnings?

Zymergen updated its second quarter 2021 earnings guidance on Tuesday, August, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $5 million-$6 million, compared to the consensus revenue estimate of $3.72 million.

What price target have analysts set for ZY?

8 brokers have issued 12-month target prices for Zymergen's stock. Their forecasts range from $7.00 to $13.00. On average, they expect Zymergen's stock price to reach $9.83 in the next year. This suggests that the stock has a possible downside of 4.3%.
View analysts' price targets for Zymergen
or view top-rated stocks among Wall Street analysts.

Who are Zymergen's key executives?

Zymergen's management team includes the following people:
  • Mr. Joshua J. Hoffmann, Co-Founder, CEO & Director (Age 50)
  • Mr. Zachariah Serber Ph.D., Co-Founder, Chief Science Officer & Director (Age 46)
  • Mr. Erik Jedidiah Dean Ph.D., Co-Founder and VP of Operations & Engineering (Age 43)
  • Ms. Enakshi Singh, Chief Financial Officer (Age 43)
  • Mr. Aaron Kimball, Chief Technology Officer (Age 37)
  • Ms. Mina Kim, Chief Legal Officer (Age 47)
  • Mike Dulin, Director of Communications
  • Mr. Jack Gold, Chief Marketing Officer
  • Ms. Judy Gilbert, Chief People Officer
  • Mr. Richard Pieters, Pres of Products

What is Joshua Hoffman's approval rating as Zymergen's CEO?

64 employees have rated Zymergen CEO Joshua Hoffman on Glassdoor.com. Joshua Hoffman has an approval rating of 62% among Zymergen's employees. This puts Joshua Hoffman in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 58.0% of employees surveyed would recommend working at Zymergen to a friend.

When did Zymergen IPO?

(ZY) raised $401 million in an initial public offering on Thursday, April 22nd 2021. The company issued 13,600,000 shares at $28.00-$31.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen, UBS Investment Bank and Lazard acted as the underwriters for the IPO.

What is Zymergen's stock symbol?

Zymergen trades on the NASDAQ under the ticker symbol "ZY."

When did Zymergen's lock-up period expire?

Zymergen's lock-up period expired on Tuesday, October 19th. Zymergen had issued 16,130,000 shares in its public offering on April 22nd. The total size of the offering was $500,030,000 based on an initial share price of $31.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are Zymergen's major shareholders?

Zymergen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Belvedere Trading LLC (0.00%) and Clarius Group LLC (0.02%).

Which institutional investors are buying Zymergen stock?

ZY stock was bought by a variety of institutional investors in the last quarter, including Belvedere Trading LLC, and Clarius Group LLC.

How do I buy shares of Zymergen?

Shares of ZY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zymergen's stock price today?

One share of ZY stock can currently be purchased for approximately $10.28.

How much money does Zymergen make?

Zymergen has a market capitalization of $1.05 billion.

How many employees does Zymergen have?

Zymergen employs 758 workers across the globe.

What is Zymergen's official website?

The official website for Zymergen is www.zymergen.com.

How can I contact Zymergen?

The company can be reached via phone at 415-801-8073 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.